Summary for Pseudo Dual responses simulations given a pseudo DLE model and the Flexible efficacy model.
Source:R/Simulations-methods.R
summary-PseudoDualFlexiSimulations-method.Rd
Summary for Pseudo Dual responses simulations given a pseudo DLE model and the Flexible efficacy model.
Usage
# S4 method for class 'PseudoDualFlexiSimulations'
summary(
object,
trueDLE,
trueEff,
targetEndOfTrial = 0.3,
targetDuringTrial = 0.35,
...
)
Arguments
- object
the
PseudoDualFlexiSimulations
object we want to summarize- trueDLE
a function which takes as input a dose (vector) and returns the true probability of DLE (vector)
- trueEff
a vector which takes as input the true mean efficacy values at all dose levels (in order)
- targetEndOfTrial
the target probability of DLE that are used at the end of a trial. Default at 0.3.
- targetDuringTrial
the target probability of DLE that are used during the trial. Default at 0.35.
- ...
Additional arguments can be supplied here for
trueDLE
andtrueEff
Value
an object of class PseudoDualSimulationsSummary
Examples
# nolint start
## If DLE and efficacy responses are considered in the simulations and the 'EffFlexi' class is used
## we need a data object with doses >= 1:
data <- DataDual(doseGrid = seq(25, 300, 25))
## First for the DLE model
## The DLE model must be of 'ModelTox' (e.g 'LogisticIndepBeta') class
DLEmodel <- LogisticIndepBeta(
binDLE = c(1.05, 1.8),
DLEweights = c(3, 3),
DLEdose = c(25, 300),
data = data
)
## for the efficacy model
Effmodel <- EffFlexi(
eff = c(1.223, 2.513), eff_dose = c(25, 300),
sigma2W = c(a = 0.1, b = 0.1), sigma2betaW = c(a = 20, b = 50), rw1 = FALSE, data = data
)
## specified the next best
mynextbest <- NextBestMaxGainSamples(
prob_target_drt = 0.35,
prob_target_eot = 0.3,
derive = function(samples) {
as.numeric(quantile(samples, prob = 0.3))
},
mg_derive = function(mg_samples) {
as.numeric(quantile(mg_samples, prob = 0.5))
}
)
## The increments (see Increments class examples)
## 200% allowable increase for dose below 300 and 200% increase for dose above 300
myIncrements <- IncrementsRelative(
intervals = c(25, 300),
increments = c(2, 2)
)
## cohort size of 3
mySize <- CohortSizeConst(size = 3)
## Stop only when 10 subjects are treated:
## very low sample size is just for illustration here
myStopping <- StoppingMinPatients(nPatients = 10)
## Specified the design
design <- DualResponsesSamplesDesign(
nextBest = mynextbest,
cohort_size = mySize,
startingDose = 25,
model = DLEmodel,
eff_model = Effmodel,
data = data,
stopping = myStopping,
increments = myIncrements
)
## specified the true DLE curve and the true expected efficacy values at all dose levels
myTruthDLE <- probFunction(DLEmodel, phi1 = -53.66584, phi2 = 10.50499)
myTruthEff <- c(
-0.5478867, 0.1645417, 0.5248031, 0.7604467,
0.9333009, 1.0687031, 1.1793942, 1.2726408,
1.3529598, 1.4233411, 1.4858613, 1.5420182
)
## specify the options for MCMC
# For illustration purpose, we use 10 burn-in and generate 100 samples
options <- McmcOptions(burnin = 10, step = 1, samples = 100)
## The simulation
## For illustration purpose only 1 simulation is produced (nsim=1).
mySim <- simulate(
object = design,
args = NULL,
trueDLE = myTruthDLE,
trueEff = myTruthEff,
trueSigma2 = 0.025,
trueSigma2betaW = 1,
nsim = 1,
seed = 819,
parallel = FALSE,
mcmcOptions = options
)
## summarize the simulation results
summary(mySim,
trueDLE = myTruthDLE,
trueEff = myTruthEff
)
#> Summary of 1 simulations
#>
#> Target probability of DLE p(DLE) used at the end of a trial was 30 %
#> The dose level corresponds to the target p(DLE) used at the end of a trial, TDEOT, was 152.6195
#> TDEOT at dose Grid was 150
#> Target p(DLE) used during a trial was 35 %
#> The dose level corresponds to the target p(DLE) used during a trial, TDDT, was 155.972
#> TDDT at dose Grid was 150
#> Number of patients overall : mean 12 (12, 12)
#> Number of patients treated above the target p(DLE) used at the end of a trial : mean 0 (0, 0)
#> Number of patients treated above the target p(DLE) used during a trial : mean 0 (0, 0)
#> Proportions of observed DLT in the trials : mean 0 % (0 %, 0 %)
#> Mean toxicity risks for the patients : mean 0 % (0 %, 0 %)
#> Doses selected as TDEOT : mean 0 (0, 0)
#> True toxicity at TDEOT : mean 0 % (0 %, 0 %)
#> Proportion of trials selecting the TDEOT: 0 %
#> Proportion of trials selecting the TDDT: 0 %
#> Dose most often selected as TDEOT: 0
#> Observed toxicity rate at dose most often selected: NaN %
#> Fitted probabilities of DLE at dose most often selected : mean NA % (NA %, NA %)
#> The summary table of the final TDEOT across all simulations
#> Min. 1st Qu. Median Mean 3rd Qu. Max.
#> 10.12 10.12 10.12 10.12 10.12 10.12
#> The summary table of the final ratios of the TDEOT across all simulations
#> Min. 1st Qu. Median Mean 3rd Qu. Max.
#> 1 1 1 1 1 1
#> The summary table of the final TDDT across all simulations
#> Min. 1st Qu. Median Mean 3rd Qu. Max.
#> 6.222 6.222 6.222 6.222 6.222 6.222
#> The summary table of dose levels, the optimal dose
#> to recommend for subsequent study across all simulations
#> Min. 1st Qu. Median Mean 3rd Qu. Max.
#> 10.12 10.12 10.12 10.12 10.12 10.12
#> The summary table of the final ratios of the optimal dose for stopping across
#> all simulations
#> Min. 1st Qu. Median Mean 3rd Qu. Max.
#> 1 1 1 1 1 1
#>
#> Stop reason triggered:
#> ≥ 10 patients dosed : 100 %
#> Target Gstar, the dose which gives the maximum gain value was 125
#> Target Gstar at dose Grid was 125
#> The summary table of the final Gstar across all simulations
#> Min. 1st Qu. Median Mean 3rd Qu. Max.
#> 250 250 250 250 250 250
#> The summary table of the final ratios of the Gstar across all simulations
#> Min. 1st Qu. Median Mean 3rd Qu. Max.
#> 2.192 2.192 2.192 2.192 2.192 2.192
#> The summary table of dose levels, the optimal dose
#> to recommend for subsequent study across all simulations
#> Min. 1st Qu. Median Mean 3rd Qu. Max.
#> 10.12 10.12 10.12 10.12 10.12 10.12
#> The summary table of the final ratios of the optimal dose for stopping across
#> all simulations
#> Min. 1st Qu. Median Mean 3rd Qu. Max.
#> 1 1 1 1 1 1
#> Fitted expected efficacy level at dose most often selected : mean NA (NA, NA)
#> Stop reason triggered:
#> ≥ 10 patients dosed : 100 %
# nolint end